Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MNP-miR-205
- Development stage
- Preclinical
- Lead developer
- The University of Texas Rio Grande Valley
- Modality
- Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
MNP-miR-205 is a nanoparticle-based RNA therapy designed to restore the levels of miR-205, a tumor-suppressor microRNA that is frequently downregulated in prostate cancer. The formulation consists of iron oxide magnetic nanoparticles (MNPs) layered with polyethylene imine (PEI) polymer to facilitate the delivery of miR-205. This theranostic agent is specifically developed to address docetaxel resistance in prostate cancer by enhancing chemosensitivity and inducing apoptosis. In preclinical studies, MNP-miR-205 demonstrated efficient cellular uptake, bypassed endosomal degradation, and significantly reduced tumor volume and weight in xenograft mouse models. The formulation also incorporates indocyanine green (ICG) dye to enable tumor tracking and imaging, providing a groundbreaking theranostic approach for prostate cancer management.
- Other names
- magnetic nanoparticle-miR-205MNP-PEI-miR-205MNP-PEI-miR205MNP-PEI-miR 205
02
Targets
RISC (RNA-induced silencing complex)TNFAIP8 (Tumor necrosis factor alpha-induced protein 8)Mediator complex subunit 1 mRNA (MED1 mRNA)miR-205 (MicroRNA 205)
Beyond the preview
Go deeper on MNP-miR-205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MNP-miR-205.